<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624698</url>
  </required_header>
  <id_info>
    <org_study_id>IG2M-105-PASN</org_study_id>
    <nct_id>NCT04624698</nct_id>
  </id_info>
  <brief_title>iStent Inject New Enrollment Post-Approval Study</brief_title>
  <official_title>iStent Inject Trabecular Micro-Bypass System New Enrollment Post-Approval Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the rate of clinically relevant complications associated with iStent inject&#xD;
      placement in the post-market setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the rate of clinically relevant complications associated with iStent inject&#xD;
      placement and stability, as determined at 36 months in the postmarket setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2020</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>iStent inject placement and stability</measure>
    <time_frame>36 Months</time_frame>
    <description>The rate of clinically relevant complications associated with iStent inject placement and stability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sight-threatening adverse events</measure>
    <time_frame>36 Months</time_frame>
    <description>Rate of occurrence of sight-threatening adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Other adverse events</measure>
    <time_frame>36 Months</time_frame>
    <description>Rate of other adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">358</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo cataract surgery and then implantation of the iStent Inject trabecular micro-bypass device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent Inject Implantation</intervention_name>
    <description>Subjects will be implanted with the iStent Injection Micro-Bypass device</description>
    <arm_group_label>Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female â‰¥ 22 years of age&#xD;
&#xD;
          2. Mild to moderate primary open-angle glaucoma&#xD;
&#xD;
          3. Scheduled to undergo cataract surgery&#xD;
&#xD;
          4. Able and willing to attend scheduled follow-up exams for three years postoperatively&#xD;
&#xD;
          5. Able and willing to provide written informed consent on the IRB approved Informed&#xD;
             Consent Form&#xD;
&#xD;
             Operative Inclusion Criterion:&#xD;
&#xD;
          6. Successful, uncomplicated cataract surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Angle closure glaucoma&#xD;
&#xD;
          2. Traumatic, malignant, uveitic, or neovascular glaucoma or discernible congenital&#xD;
             anomalies of the anterior chamber angle&#xD;
&#xD;
          3. Retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of&#xD;
             condition that may cause elevated episcleral venous pressure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jason Schmitt, O.D.</last_name>
    <phone>949-481-0401</phone>
    <email>jschmitt@glaukos.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerry Stephens, O.D.</last_name>
    <email>kstephens@glaukos.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye Doctors of Arizona, PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Schmitt, O.D.</last_name>
      <phone>949-481-0401</phone>
      <email>jschmitt@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wolstan and Goldberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Schmitt, O.D.</last_name>
      <phone>949-481-0401</phone>
      <email>jschmitt@glaukos.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glaucoma Associates of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Schmitt, O.D.</last_name>
      <phone>949-481-0401</phone>
      <email>jschmitt@glaukos.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

